Alpha Mannosidosis Market Report 2026

The alpha mannosidosis market size has grown rapidly in recent years. It will grow from $17.87 billion in 2025 to $21 billion in 2026 at a compound annual growth rate (CAGR) of 17.5%. The growth in the historic period can be attributed to limited diagnostic infrastructure, low disease awareness, reliance on conventional therapies, fragmented treatment guidelines, restricted R&D funding.

The alpha mannosidosis market size is expected to see rapid growth in the next few years. It will grow to $39.41 billion in 2030 at a compound annual growth rate (CAGR) of 17%. The growth in the forecast period can be attributed to increased investment in gene therapies, growing adoption of enzyme replacement therapies, expansion of healthcare infrastructure, technological advancements in diagnostics, regulatory incentives for rare diseases. Major trends in the forecast period include early genetic screening programs, development of orphan drugs, personalized enzyme replacement therapy, expansion of rare disease clinics, collaborative research initiatives.

The rising demand for precision medicine is expected to drive the growth of the alpha mannosidosis market. Precision medicine tailors healthcare to individual patient differences in genes, environments, and lifestyles, enabling optimized treatment and prevention strategies. Advances in genomic technologies and data analytics allow for more accurate identification of genetic variations and their health impacts. Growing awareness of the limitations of standard treatments has further fueled interest in personalized therapies. This approach supports the development of targeted treatments for rare disorders like alpha mannosidosis, addressing specific genetic mutations and patient profiles. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. Therefore, the rising demand for precision medicine is fueling the growth of the alpha mannosidosis market.

Key companies in the alpha mannosidosis market are focusing on enzyme replacement therapies to treat this rare disorder. Enzyme replacement therapy supplies exogenous alpha-mannosidase, reducing the accumulation of mannose-rich oligosaccharides in tissues and organs - a hallmark of alpha-mannosidosis that contributes to disease pathology. For example, in February 2023, Chiesi Global Rare Diseases, a US-based pharmaceutical company, launched Lamzede (velmanase alfa), the first enzyme replacement therapy approved in the United States for alpha-mannosidosis. Lamzede restores normal cellular activity by mimicking the body’s natural alpha-mannosidase, administered as a 10 mg injection once weekly.

In April 2023, Chiesi Farmaceutici, an Italy-based pharmaceutical company, acquired Amryt Pharma for $1.25 billion. This acquisition expanded Chiesi’s Global Rare Diseases division by adding Amryt Pharma’s approved commercial products for rare diseases to its portfolio. Amryt Pharma is a UK-based pharmaceutical company specializing in the development and delivery of innovative treatments for rare diseases.

Major companies operating in the alpha mannosidosis market are Chiesi Farmaceutici S.p.A., Cipla, Daiichi Sankyo Company, Ultragenyx Pharmaceutical Inc, Mitsubishi Tanabe Pharma, Zymenex A/S, Albumedix Ltd, Freeline Therapeutics, Avectas, DiNAQOR AG, Vivet Therapeutics, Herantis Pharma Plc, PTC Therapeutics, Biocad, Sanofi, Orchard Therapeutics, Shire Pharmaceuticals, Amicus Therapeutics, BioMarin Pharmaceutical Inc, Genzyme.

North America was the largest region in the alpha mannosidosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha mannosidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alpha mannosidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the alpha mannosidosis market by increasing the cost of imported biopharmaceuticals and specialized diagnostic equipment. This has affected regions heavily reliant on imports, particularly North America and Europe, and segments like enzyme replacement therapy and gene therapy. Manufacturers are adapting by localizing production and optimizing supply chains. While tariffs pose challenges, they may also encourage domestic manufacturing and innovation in cost-effective treatments.

The alpha mannosidosis market research report is one of a series of new reports that provides alpha mannosidosis market statistics, including alpha mannosidosis industry global market size, regional shares, competitors with a alpha mannosidosis market share, detailed alpha mannosidosis market segments, market trends and opportunities, and any further data you may need to thrive in the alpha mannosidosis industry. This alpha mannosidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Alpha mannosidosis is a rare genetic disorder in which the body’s cells cannot properly break down certain complex sugars. This leads to sugar accumulation that affects multiple organs and systems, including the central nervous system, with symptoms varying widely among individuals.

The main therapies for alpha mannosidosis include bone marrow transplant (BMT), enzyme replacement therapy (ERT), and others. Bone marrow transplant involves replacing defective marrow with healthy marrow, while enzyme replacement therapy provides the missing or deficient enzyme to affected individuals. The disorder is classified into Type I, Type II, and Type III, and these therapies are delivered across settings such as hospitals and specialized clinics.

The alpha mannosidosis market includes revenues earned by entities by intellectual disability, skeletal abnormalities, hearing loss, and muscle weakness. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.